LVIVO-TaVec100 product

Phase 1Biologic

TThe First Affiliated Hospital with Nanjing Medical University

LVIVO-TaVec100 product is one of 3 biologic programs targeting Relapsed/Refractory B-cell Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractory B-Cell MalignanciesRecruiting

Relapsed/refractory B-Cell MalignanciesPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Relapsed/refractory B-Cell Malignancies

#DrugCompanyPhaseTrials

SYS6055

BBeijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd

Phase 1

1 2

LVIVO-TaVec100 product

TThe First Affiliated Hospital with Nanjing Medical University

Phase 1

1 3

CD19+

SSt. Jude Children's Research Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

Relapsed/refractory B-Cell Malignancies

NCT07002112

Clinical

Trials by Indication[1]

Relapsed/Refractory B-cell Malignancies1 trial

The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT07002112·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LVIVO-TaVec100 product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LVIVO-TaVec100 product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LVIVO-TaVec100 product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital with Nanjing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TThe First Affiliated Hospital with Nanjing Medical University

LVIVO-TaVec100 product

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Relapsed/Refractory B-cell Malignancies1 trial

References

Drug Info

Quick Facts

Related News